[go: up one dir, main page]

EA200300322A1 - 4-галогенированные 17-метиленстероиды, способ их получения и содержащие эти соединения фармацевтические композиции - Google Patents

4-галогенированные 17-метиленстероиды, способ их получения и содержащие эти соединения фармацевтические композиции

Info

Publication number
EA200300322A1
EA200300322A1 EA200300322A EA200300322A EA200300322A1 EA 200300322 A1 EA200300322 A1 EA 200300322A1 EA 200300322 A EA200300322 A EA 200300322A EA 200300322 A EA200300322 A EA 200300322A EA 200300322 A1 EA200300322 A1 EA 200300322A1
Authority
EA
Eurasian Patent Office
Prior art keywords
pharmaceutical compositions
methylenestroids
halogenated
compounds
receiving
Prior art date
Application number
EA200300322A
Other languages
English (en)
Other versions
EA006387B1 (ru
Inventor
Бернд Менценбах
Вальтер Эльгер
Петер Дрёшер
Александр Хиллиш
Гюнтер Кауфманн
Ханс-Удо Швайкерт
Герд Мюллер
Original Assignee
Йенафарм Гмбх Унд Ко. Кг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Йенафарм Гмбх Унд Ко. Кг filed Critical Йенафарм Гмбх Унд Ко. Кг
Publication of EA200300322A1 publication Critical patent/EA200300322A1/ru
Publication of EA006387B1 publication Critical patent/EA006387B1/ru

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J13/00Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J13/00Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17
    • C07J13/007Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17 with double bond in position 17 (20)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16Masculine contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18Feminine contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/10Anti-acne agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/14Drugs for dermatological disorders for baldness or alopecia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28Antiandrogens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34Gestagens

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Urology & Nephrology (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

В заявке описываются 17-метиленстероиды, способ их получения и содержащие эти соединения фармацевтические композиции. Предлагаемые в изобретении соединения обладают профилем действия смешанного характера, проявляющегося в том, что, с одной стороны, они действуют как ингибиторы 5α-редуктазы и одновременно как гестагены. Благодаря этому они пригодны для лечения заболеваний определенных органов и тканей у мужчин и женщин, обусловленных повышенным уровнем андрогенов. В сочетании с другими гормональными веществами, такими как эстроген, тестостерон, соответственно высокоактивный андроген, соединения по изобретению могут применяться также в качестве противозачаточных средств как для женщин, так и для мужчин.Международная заявка была опубликована вместе с отчетом о международном поиске.
EA200300322A 2000-09-04 2001-08-29 4-галогенированные 17-метиленстероиды, способ их получения и содержащие эти соединения фармацевтические композиции EA006387B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10043846A DE10043846A1 (de) 2000-09-04 2000-09-04 17-Methylensteroide, Verfahren zu deren Herstellung und diese Verbindung enthaltende pharmazeutische Zusammensetzungen
PCT/EP2001/009943 WO2002019971A1 (de) 2000-09-04 2001-08-29 4-halogenierte 17-methylensteroide, verfahren zu deren herstellung und diese verbindungen enthaltende pharmazeutische zusammensetzungen

Publications (2)

Publication Number Publication Date
EA200300322A1 true EA200300322A1 (ru) 2003-10-30
EA006387B1 EA006387B1 (ru) 2005-12-29

Family

ID=7655148

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200300322A EA006387B1 (ru) 2000-09-04 2001-08-29 4-галогенированные 17-метиленстероиды, способ их получения и содержащие эти соединения фармацевтические композиции

Country Status (28)

Country Link
EP (1) EP1423407B1 (ru)
JP (1) JP2004513084A (ru)
KR (1) KR100530816B1 (ru)
CN (1) CN1262560C (ru)
AT (1) ATE319733T1 (ru)
AU (2) AU2002210470B2 (ru)
BG (1) BG107594A (ru)
BR (1) BR0113618A (ru)
CA (1) CA2421302C (ru)
DE (2) DE10043846A1 (ru)
DK (1) DK1423407T3 (ru)
EA (1) EA006387B1 (ru)
EE (1) EE05186B1 (ru)
ES (1) ES2260294T3 (ru)
HR (1) HRP20030256A2 (ru)
HU (1) HUP0300936A3 (ru)
IL (2) IL154666A0 (ru)
ME (1) MEP14408A (ru)
MX (1) MXPA03001912A (ru)
NO (1) NO325012B1 (ru)
NZ (1) NZ524485A (ru)
PL (1) PL360669A1 (ru)
PT (1) PT1423407E (ru)
RS (1) RS50305B (ru)
SK (1) SK286757B6 (ru)
UA (1) UA74592C2 (ru)
WO (1) WO2002019971A1 (ru)
ZA (1) ZA200301715B (ru)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10141984A1 (de) * 2001-08-28 2003-03-20 Jenapharm Gmbh Neue 17-Methylen-4-azasteroide
US7199115B2 (en) 2004-04-19 2007-04-03 Schering Ag 17α-fluorosteroids, pharmaceutical compositions containing 17α-fluorosteroids and a method of making them
DE202007019049U1 (de) * 2007-11-05 2010-05-12 Bayer Schering Pharma Aktiengesellschaft Verwendung eines Gestagens in Kombination mit einem Estrogen zur Prophylaxe der Laktoseintoleranz bei der oralen Kontrazeption

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2611773A (en) * 1951-08-21 1952-09-23 Upjohn Co Estradiol 17-cyclopenetanepropionate
US3146239A (en) * 1957-09-23 1964-08-25 Syntex Corp 4-halo-19-nor-progesterone
US3232960A (en) * 1959-10-08 1966-02-01 Upjohn Co 3-keto-4-fluoro- and 3-keto-4,4-difluorosteroids and process
US3661940A (en) * 1970-04-13 1972-05-09 Sandoz Ag Derivatives of 21-methyl-19-norpregnanes
US4389345A (en) * 1981-10-09 1983-06-21 G.D. Searle & Co. 3-Oxoestra-17-acetonitrile and unsaturated analogs
US5994334A (en) * 1997-02-05 1999-11-30 University Of Maryland Androgen synthesis inhibitors
EP1409512A1 (en) * 2000-06-27 2004-04-21 Aventis Pharma S.A. 20-fluoro-17(20)-vinyl steroids as inhibitors of c17-20-lyase and 5-alpha reductase

Also Published As

Publication number Publication date
JP2004513084A (ja) 2004-04-30
DK1423407T3 (da) 2006-07-03
AU1047002A (en) 2002-03-22
PT1423407E (pt) 2006-07-31
KR100530816B1 (ko) 2005-11-25
CA2421302A1 (en) 2003-03-03
YU16403A (sh) 2006-05-25
IL154666A (en) 2008-12-29
CN1452628A (zh) 2003-10-29
ZA200301715B (en) 2004-08-13
SK2442003A3 (en) 2003-08-05
IL154666A0 (en) 2003-09-17
MXPA03001912A (es) 2004-07-08
RS50305B (sr) 2009-09-08
HK1060135A1 (en) 2004-07-30
NO325012B1 (no) 2008-01-14
UA74592C2 (en) 2006-01-16
BG107594A (bg) 2003-09-30
CA2421302C (en) 2007-08-14
ES2260294T3 (es) 2006-11-01
WO2002019971A1 (de) 2002-03-14
AU2002210470B2 (en) 2006-07-20
KR20030028836A (ko) 2003-04-10
EE05186B1 (et) 2009-06-15
HUP0300936A2 (hu) 2003-11-28
NZ524485A (en) 2005-11-25
DE50109175D1 (de) 2006-05-04
WO2002019971A9 (de) 2002-08-08
BR0113618A (pt) 2003-07-15
CN1262560C (zh) 2006-07-05
DE10043846A1 (de) 2002-04-04
EE200300087A (et) 2005-02-15
ATE319733T1 (de) 2006-03-15
EP1423407A1 (de) 2004-06-02
NO20030989L (no) 2003-05-02
PL360669A1 (en) 2004-09-20
NO20030989D0 (no) 2003-03-03
SK286757B6 (sk) 2009-05-07
MEP14408A (en) 2010-06-10
HUP0300936A3 (en) 2010-01-28
EP1423407B1 (de) 2006-03-08
EA006387B1 (ru) 2005-12-29
HRP20030256A2 (en) 2005-10-31

Similar Documents

Publication Publication Date Title
EA200201000A1 (ru) Гормон-заместительная терапия
ATE128362T1 (de) Kombinationstherapie zur behandlung von estrogenempfindlichen erkrankungen.
FR2814074B1 (fr) Nouvelles compositions estro-progestatives topiques a effet systemique
EA200600964A1 (ru) Фармацевтический препарат для непрерывного гормонального лечения в течение периода времени более длительного, чем 21-28 дней, включающий две композиции эстрогена и/или прогестина
ATE460939T1 (de) Verfahren zur behandlung von erektionsstörungen und steigerung der libido bei männern
MXPA03001859A (es) Metodo para incrementar en la mujer testosterona y concentraciones de esteroides relacionados.
BR0114801A (pt) Composto modulador receptor de androgênio seletivo de tecido, composição, composição farmacêutica, método para a ligação de um composto modulador receptor de androgênio seletivo a um receptor de androgênio, método para a modulação da espermatogênese em um indivìduo, método de terapia hormonal, método para o tratamento para um indivìduo tendo uma condição relacionada a um hormÈnio, método para o tratamento para um indivìduo tendo c‰ncer prostático e método para a determinação da presença de um composto
YU54602A (sh) Drospirenon za terapiju zamene hormona
BR9807828A (pt) Composições e método para a suplementação de testosterona em mulheres com sintomas de deficiência de testosterona
EA200301022A1 (ru) Гормональная заместительная терапия
EA200401210A1 (ru) Андрогенная фармацевтическая композиция и способ для лечения депрессии
EA200300322A1 (ru) 4-галогенированные 17-метиленстероиды, способ их получения и содержащие эти соединения фармацевтические композиции
HUP9901505A2 (hu) Dehidroepiandroszteron és aromatázgátlók kombinációja és e kombináció felhasználása férfiak relatív és abszolút androgénhiányának kezelésére szolgáló gyógyszerkészítmények előállítására
AR043013A1 (es) Composicion farmaceutica destinada al tratamiento de la endometriosis
EE200300310A (et) Ravimkompositsioon, mis sisaldab östrogeeni ja muid hormoone kombinatsioonis askorbaadi, lüsiini, proliini ja teiste toimeainetega, ning selle kasutamine
AR048829A1 (es) 17alfa - fluoroesteroides con actividad inhibidora de 5 alfa-reductasa; composiciones farmaceuticas que los contienen y su uso en la preparacion de medicamentos para el tratamiento de enfermedades cancerosas influidas por androgenos.
HRP20070360A2 (hr) Drospirenon za hormonsku nadomjesnu terapiju
TH75723A (th) 17 อัลฟา -ฟลูออโรสเทอรอยด์
NZ605707A (en) Reduction of side effects from aromatase inhibitors used for treating breast cancer
HRP20020666A8 (en) Drospirenone for hormone replacement therapy

Legal Events

Date Code Title Description
PC1A Registration of transfer to a eurasian application by force of assignment
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ KZ KG MD TJ TM

PD4A Registration of transfer of a eurasian patent in accordance with the succession in title
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): BY RU